Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewImmunology Open Access | 10.1172/jci.insight.193054

Rheumatoid arthritis synovial fibroblasts modulate T cell activation

Melissa R. Romoff,1 Preethi K. Periyakoil,2 Edward F. DiCarlo,3 Daniel Ramirez,3 Susan M. Goodman,4 Christina S. Leslie,2 Alexander Y. Rudensky,5 Laura T. Donlin,1 and Melanie H. Smith1

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Romoff, M. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Periyakoil, P. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by DiCarlo, E. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Ramirez, D. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Goodman, S. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Leslie, C. in: PubMed | Google Scholar |

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Rudensky, A. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Donlin, L. in: PubMed | Google Scholar

1HSS Research Institute, Hospital for Special Surgery, New York, United States of America

2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States of America

3Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, United States of America

4Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, United States of America

5Weill Cornell Medical College, New York, United States of America

Find articles by Smith, M. in: PubMed | Google Scholar

Published October 7, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.193054.
Copyright © 2025, Romoff et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published October 7, 2025 - Version history
View PDF
Abstract

In the rheumatoid arthritis (RA) synovium, resident fibroblast-like synoviocytes (FLS) express MHC class II molecules (HLA-D) but lack the co-stimulatory signals typically required for T cell activation. Here, we demonstrate that antigen presentation by FLS induces a distinct T cell activation state characterized by high CD69, yet reduced CD25 and HLA-DR expression, suppressed proliferation, and decreased effector cytokine production compared to professional antigen presenting cells (APCs), such as macrophages. FLS were also capable of suppressing macrophage-induced T cell activation, underscoring their dominant immunomodulatory role in the synovial microenvironment. Mechanistically, we identify indoleamine 2,3-dioxygenase (IDO1)-mediated tryptophan depletion as the primary driver of FLS-induced T cell hypo-responsiveness. Spatial transcriptomics revealed colocalization of IDO1 and CD69 within ectopic lymphoid structures in RA synovium, further supporting the in vivo relevance of this pathway. These findings provide the groundwork for positioning FLS as critical T cell regulators in RA and highlight the importance of preserving their immunosuppressive properties when therapeutically targeting pathogenic FLS functions.

Graphical Abstract
graphical abstract
Supplemental material

View Supplemental tables

View

Version history
  • Version 1 (October 7, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts